SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports ...
Non-Alcoholic Steatohepatitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present ...
The current pharmaceutical landscape demands a change in mindset. Success requires balancing speed, cost and quality while ...
Artificial intelligence (AI) is rapidly transforming clinical trials by dramatically reducing timelines and costs, accelerating patient-centered drug development and creating more resilient and ...
This study reviewed all industry-sponsored phase I clinical trial protocols activated at one of eight Sarah Cannon Research Institute drug development units between 2021 and 2024. The review focused ...
Clinical Trials Arena on MSN
Neuphoria scraps social anxiety hopeful after Phase III miss
Analysts from William Blair and GlobalData critiqued the trial design for social anxiety disorder, though the latter notes ...
The main market opportunities in the eosinophilic esophagitis pipeline include focusing on novel therapeutic approaches, potential development of first-in-class treatments like IRL201104, targeting ...
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the findings of new research by the Tufts Center for the Study of Drug Development ...
IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / / Medicus Pharma Ltd.
Enrollment for this Phase 3 program follows positive Phase 1/2 data demonstrating that ADX-324 achieved significant and durable suppression of prekallikrein (PKK) protein levels with a favorable ...
Initial results from the dose escalation part of the first-in-human phase 1/2 trial of DS-3939 demonstrated promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback